Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the stocks that could 10x over the next 5 years. On March 3, H.C. Wainwright reaffirmed its Buy rating and $80 price target on Beam Therapeutics Inc. (NASDAQ:BEAM). The rating follows Beam’s fourth-quarter and full-year 2025 results, which showed considerable progress in the company’s product pipeline.

The company announced BEAM-304, an innovative gene editing program for phenylketonuria, with an experimental new medication filing expected in 2026. Meanwhile, new data from BEAM-302 in alpha-1 antitrypsin deficiency continues on schedule for the first quarter of 2026, including information on an FDA-guided prospective accelerated pivotal path.

Beam Therapeutics Inc. (NASDAQ:BEAM) also revealed a $500 million senior secured, long-term non-dilutive contract with Sixth Street, which will serve as support for the possible commercial launch of Risto-Cel. The company reported $1.25 billion in cash, cash equivalents, and marketable securities at the end of 2025. With the expected minimum $200 million pull from Sixth Street, the company forecasts a financial runway through mid-2029.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company developing precision genetic medicines using its proprietary base-editing technology. Its main products include investigational therapies such as BEAM-101 and BEAM-302.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. 

Disclosure: None. Follow Insider Monkey on Google News.